Gastroenterology

About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.

Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.

The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.

Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.

Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.

Ulcerative colitis patients with fatigue are more likely to be unemployed, have moderate or severe disease, and higher Mayo scores.

Data show males, patients with high BMI correlated with higher FAST score in HCV care.

Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.

Data show a 23.5% increase in influenza vaccination rates.

Data show biologic therapy was not associated with ICU admission or death due to infection.

C difficile and sepsis infections can be especially difficult to treat.

SER-109 resulted in a 73% reduction in relative risk for CDI over 8 weeks.

Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.

There is a substantial health care cost for CDI patients with sepsis.

In data presented at DDW, researchers find a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.

The researchers developed a computerized clinical decision support tool to help clinicians prescribe probiotics.

A large proportion of HCV patients remain undiagnosed, particularly in the older population.

Vonoprazan has shown more potent acid inhibitory effects than PPI.

An electronic reminding system helped identify 3783 patients with anti-HCV antibody documentation.

The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with Crohn’s disease was a predictor of disease severity.

The majority of adverse effects reported were considered mild.

More than 40% of the treatment arm of the placebo-controlled trial achieved a complete renal response.

Histologic scores in the endoscopically involved mucosa of index biopsies not linked to subsequent extension of ulcerative colitis.

The CDC currently recommends every pregnant woman screened for hepatitis C virus.

Females and older patients had higher rates of hospitalizations with CDI than males and younger patients.